COVID-19大流行期间骨转移和癌症治疗所致骨丢失的管理:国际视角与建议
该文基于2020年7月癌症与骨学会(Cancer and Bone Society)虚拟会议上专家组的经验分享,以及随后向研讨会参与者发送的国际问卷(70名受访者,来自9个国家,多数为美国39%,其次英国19%;50名临床医生,其中64%为肿瘤内科医生;20名非临床人员;肿瘤类型以乳腺癌65%、前列腺癌27%为主),分析了COVID-19大流行期间骨转移和癌症治疗所致骨丢失管理受到的影响,并提出了在大流行期间调整正常指南以保护骨骼健康的理由和建议。
要点
- 70名受访者中,58%报告常规CT扫描延迟,48%报告标准骨扫描延迟,46%报告MRI扫描延迟,但急诊扫描受影响较小。
- 31%的受访者报告骨痛姑息性放疗延迟,治疗常仅涉及单次剂量而无分次。
- 35%的受访者报告骨痛预防性手术延迟或取消。
- 静脉双膦酸盐和皮下地舒单抗的可及性是一大问题,通过在家或当地诊所提供药物给药、减少给药频率或改为在家口服双膦酸盐来缓解。
- 问卷还显示临床和实验室研究受到有害的延迟或完全停止。
适用人群与场景
- 所有实体瘤类型和骨髓瘤的转移性骨病患者
- 乳腺癌辅助双膦酸盐治疗患者
- 癌症治疗所致骨丢失患者
处置流程与药物剂量
- 通过在家或当地诊所提供药物给药、减少给药频率或改为在家口服双膦酸盐,以缓解静脉双膦酸盐和皮下地舒单抗可及性问题。
- 骨痛姑息性放疗常仅涉及单次剂量而无分次。
研究设计与关键结果
- 问卷于2020年7月癌症与骨学会虚拟会议后发送,70名受访者来自9个国家(美国39%,英国19%),包括50名临床医生(64%为肿瘤内科医生)和20名非临床人员,肿瘤类型以乳腺癌65%、前列腺癌27%为主。
- 58%的受访者报告常规CT扫描延迟,48%报告标准骨扫描延迟,46%报告MRI扫描延迟,急诊扫描受影响较小。
- 31%的受访者报告骨痛姑息性放疗延迟,治疗常仅涉及单次剂量而无分次。
- 35%的受访者报告骨痛预防性手术延迟或取消。
- 静脉双膦酸盐和皮下地舒单抗的可及性是一大问题,通过在家或当地诊所提供药物给药、减少给药频率或改为在家口服双膦酸盐来缓解。
- 问卷还显示临床和实验室研究受到有害的延迟或完全停止。
证据类型、等级与局限
- 证据类型:国际专家会议及问卷调查(专家意见)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者提出在大流行期间调整正常指南以保护骨骼健康的理由和建议。
- 为缓解药物可及性问题,可考虑在家或当地诊所提供药物给药、减少给药频率或改为在家口服双膦酸盐。
- 骨痛姑息性放疗可考虑单次剂量而无分次。
指南或共识出处
- Cancer and Bone Society虚拟会议(2020年7月)
- 本文提出的建议
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Optimum management of patients with cancer during the COVID-19 pandemic has proved extremely challenging. Patients, clinicians and hospital authorities have had to balance the risks to patients of attending hospital, many of whom are especially vulnerable, with the risks of delaying or modifying cancer treatment. Those whose care has been significantly impacted include patients suffering from the effects of cancer on bone, where delivering the usual standard of care for bone support has often not been possible and clinicians have been forced to seek alternative options for adequate management. At a virtual meeting of the Cancer and Bone Society in July 2020, an expert group shared experiences and solutions to this challenge, following which a questionnaire was sent internationally to the symposium's participants, to explore the issues faced and solutions offered. 70 respondents, from 9 countries (majority USA, 39%, followed by UK, 19%) included 50 clinicians, spread across a diverse range of specialties (but with a high proportion, 64%, of medical oncologists) and 20 who classified themselves as non-clinical (solely lab-based). Spread of clinician specialty across tumour types was breast (65%), prostate (27%), followed by renal, myeloma and melanoma. Analysis showed that management of metastatic bone disease in all solid tumour types and myeloma, adjuvant bisphosphonate breast cancer therapy and cancer treatment induced bone loss, was substantially impacted. Respondents reported delays to routine CT scans (58%), standard bone scans (48%) and MRI scans (46%), though emergency scans were less affected. Delays in palliative radiotherapy for bone pain were reported by 31% of respondents with treatments often involving only a single dose without fractionation. Delays to, or cancellation of, prophylactic surgery for bone pain were reported by 35% of respondents. Access to treatments with intravenous bisphosphonates and subcutaneous denosumab was a major problem, mitigated by provision of drug administration at home or in a local clinic, reduced frequency of administration or switching to oral bisphosphonates taken at home. The questionnaire also revealed damaging delays or complete stopping of both clinical and laboratory research. In addition to an analysis of the questionnaire, this paper presents a rationale and recommendations for adaptation of the normal guidelines for protection of bone health during the pandemic.
参考来源
- Brown JE, Wood SL, Confavreux C, et al. Management of bone metastasis and cancer treatment-induced bone loss during the COVID-19 pandemic: An international perspective and recommendations. J Bone Oncol. 2021. PMID: 34131559. doi:10.1016/j.jbo.2021.100375
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。